Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512359 | 0.98 | GPR119 (0.56) | GPR119FAAHGNAI3GNAO1GNAI1 | |
| SCHEMBL8151168 | 0.94 | GPR119 (0.55) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL850478 | 0.91 | GPR119 (0.50) | GPR119FAAHGNAI3GNAO1GNAI1 | |
| SCHEMBL19852544 | 0.91 | HPGD (0.50) | GPR119FAAHHPGDPKMMEN1 | |
| SCHEMBL19032685 | 0.89 | GPR119 (0.49) | GPR119FAAH | |
| SCHEMBL19040791 | 0.89 | GPR119 (0.50) | GPR119FAAHGNAI3GNAO1GNAI1 | |
| SCHEMBL15085741 | 0.89 | GPR119 (0.59) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL19852378 | 0.89 | HPGD (0.51) | GPR119FAAHHPGDPKMMEN1 | |
| SCHEMBL21142602 | 0.89 | HPGD (0.55) | GPR119FAAHHPGDMEN1HTT | |
| SCHEMBL23499817 | 0.88 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | GPR119 3791/4885FAAH 4345/4885GNAI3 2357/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GPR119 3741/4885FAAH 4290/4885GNAI3 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.